Exercise Capacity

SAN DIEGO — Exercise capacity improved among adults with pulmonary arterial hypertension taking a macitentan-tadalafil tablet over 68 weeks, according to research presented at the American Thoracic Society International Conference.

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten improved exercise capacity and quality of life compared with placebo, according to the results of the SEQUOIA-HCM trial.

Adults with mild stroke had higher odds of maintaining similar levels of physical activity or being more active with greater resources available in their area, according to research presented at the International Stroke Conference.

Compared with placebo, aficamten was associated with increased exercise capacity and improvements in symptoms of obstructive hypertrophic cardiomyopathy, according to topline results of the phase 3 SEQUOIA-HCM trial.

Consuming nitrate-rich beetroot juice daily for 12 weeks resulted in decreased blood pressure and better 6-minute walk distance in patients with COPD compared with placebo, according to data published in European Respiratory Journal.

Researchers identified a subgroup of patients with HF with preserved ejection fraction and elevated pulmonary capillary wedge pressure that may benefit from splanchnic ablation for volume management.

In patients with peripheral artery disease who underwent a 3-month supervised exercise training program, the greatest improvements in functional performance occurred during the first 2 months, researchers reported.

Inhaled treprostinil was safe in patients with pulmonary hypertension associated with interstitial lung disease over 1 year and sustained improved exercise capacity, according to study results published in European Respiratory Journal.

For patients with COPD hospitalized with acute exacerbations, pulmonary rehabilitation yielded better exercise capacity and quality of life vs. usual care, according to study results published in Annals of the American Thoracic Society.